Potential new therapeutic targets for preeclampsia discovered
· Medical Xpressedited by Sadie Harley, reviewed by Robert Egan
Sadie Harley
Scientific Editor
Meet our editorial team
Behind our editorial process
Robert Egan
Senior Editor
Meet our editorial team
Behind our editorial process Editors' notes
This article has been reviewed according to Science X's editorial process and policies. Editors have highlighted the following attributes while ensuring the content's credibility:
fact-checked
peer-reviewed publication
trusted source
proofread
The GIST Add as preferred source
Unusual behavior in the cells of mothers and babies with preeclampsia may provide new therapeutic targets for the condition, a new UCL-led study finds.
Preeclampsia is a leading cause of maternal and fetal mortality, affecting 2% to 4% of pregnancies globally. The condition causes the mother's blood pressure to become too high, which can affect blood flow to the baby and cause symptoms like swelling, headaches, blurred vision and pain under the ribs.
If left untreated, it can harm the mother's health, slow the baby's growth and, in severe cases, be life-threatening. However, there is currently no cure.
Now, in a new study published in Science Advances, scientists from UCL and University College London Hospitals (UCLH) have discovered that a combination of stressed placental cells, poorly functioning blood vessels and an overactive immune response contribute to the condition.
Previous research has focused only on the placenta (an organ developed by the mother during pregnancy that helps support a baby's growth) and not on the tissues surrounding it.
The researchers hope that their findings will provide new therapeutic targets for preeclampsia and a potential way to treat those with the condition.
A wider view of pregnancy tissues
Senior author Professor Sara Hillman (UCL EGA Institute for Women's Health) said, "We studied individual cells from both the mother and the baby to see how their activity changes in healthy pregnancies compared with preeclampsia.
"This helped us to confirm some changes already suspected in the condition and also discover new ones."
For their research, the team studied 20 pregnant women—10 of whom had severe preeclampsia and 10 who did not—who were recruited at UCLH.
They used genomic testing to investigate individual cells in the placenta and other tissues (myometrium and chorioamniotic membranes) where cells from the developing baby and mother meet.
The team then compared these cells with those from healthy and preeclamptic pregnancies at different gestational ages.
They did this using novel technology that helped them read the genetic information of thousands of individual cells at a time, understand what each cell was doing and where it was located in a tissue, and build a detailed picture of pregnancy.
Stress, blood flow and immunity
They found that in preeclamptic pregnancies in which babies were born premature (before 37 weeks) during the third trimester, cells in the placenta showed signs of stress and low oxygen and did not use energy in the normal way.
Additionally, they found that some cells responsible for reshaping the mother's blood vessels were not working properly, which may affect blood flow to the baby.
Crucially, there were also signs of an overactive immune response—not just in the placenta but also in nearby tissues and even in the mother's blood. This, along with other stress molecules released by the placenta, helps explain why preeclampsia affects the whole body and can become a serious condition.
The researchers hope these findings will help find treatments for the condition and save lives.
Early targets for severe cases
Co-lead author Dr. Yara Sanchez Corrales (UCL Great Ormond Street Institute of Child Health) said, "These findings point to specific biological processes that could be targeted with treatments. Acting early in pregnancy, especially in more severe early-onset cases, could help improve outcomes and reduce the high risks associated with severe preeclampsia.
"We hope that our findings may set us on the path to reducing premature births and fatalities associated with preeclampsia."
Co-lead author Theodoros Xenakis (UCL Great Ormond Street Institute of Child Health) said, "Future studies may provide an even clearer picture of the biological changes linked to the disease by including more participants and using even more precise methods."
Both Sanchez Corrales and Xenakis are in Professor Sergi Castellano's lab at the UCL Great Ormond Street Institute of Child Health.
Study limitations
The researchers were limited by the small number of donors when looking at very subtle gene changes in some rare cell types. Future studies that include more people and use even higher-resolution methods may uncover additional, more detailed biological changes linked to the disease.
Publication details
Yara E Sanchez-Corrales et al, Spatially resolved fetal and maternal cell contributions to severe preeclampsia across gestation, Science Advances (2026). DOI: 10.1126/sciadv.aed8964. www.science.org/doi/10.1126/sciadv.aed8964
Journal information: Science Advances
Key medical concepts
Clinical categories
Obstetrics & gynecologyPregnancyWomen's health Provided by University College London Who's behind this story?
Sadie Harley
BSc Life Sciences & Ecology. Microbiology lab background with pharmaceutical news experience in oil, gas, and renewable industries. Full profile →
Robert Egan
Bachelor's in mathematical biology, Master's in creative writing. Well-traveled with unique perspectives on science and language. Full profile →
Citation: Potential new therapeutic targets for preeclampsia discovered (2026, July 24) retrieved 24 July 2026 from https://medicalxpress.com/news/2026-07-potential-therapeutic-preeclampsia.html This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.